Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pooling data for stability studies: testing the equality of batch degradation slopes.

S J Ruberg1, J W Stegeman

  • 1Department of Biostatistics, Marion Merrell Dow Inc., Cincinnati, Ohio 45215.

Biometrics
|September 1, 1991
PubMed
Summary

This study introduces a new method for pharmaceutical stability testing, calculating significance levels based on desired statistical power. This approach improves batch data pooling for accurate shelf-life determination.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paradigm shifts in clinical trials enabled by information technology.

Statistics in medicine·2001
Same author

Detecting dose response with contrasts.

Statistics in medicine·2000
Same author

Randomization tests for assessing the equality of area under curves for studies using destructive sampling.

Journal of applied toxicology : JAT·1996
Same author

Factorial dose-response studies using frequency and magnitude of dose.

Journal of biopharmaceutical statistics·1996
Same author

Dose response studies. I. Some design considerations.

Journal of biopharmaceutical statistics·1995
Same author

Dose response studies. II. Analysis and interpretation.

Journal of biopharmaceutical statistics·1995

Area of Science:

  • Pharmaceutical Science
  • Biostatistics
  • Drug Development

Background:

  • Pharmaceutical products require rigorous stability monitoring to ensure drug content over time.
  • Current shelf-life determination relies on the FDA Guideline, using a significance level of 0.25 for batch difference testing.
  • High significance levels in preliminary testing may compromise the power to detect batch variations.

Purpose of the Study:

  • To present an alternative approach for pharmaceutical stability analysis.
  • To calculate the significance level required to achieve a fixed statistical power for detecting batch differences.
  • To compare the performance of the proposed method with the existing FDA guideline.

Main Methods:

  • Modeling drug product degradation based on stability study data.

Related Experiment Videos

  • Implementing a procedure where statistical power is fixed, and the significance level is data-derived.
  • Comparing pooled vs. unpooled batch data analysis based on calculated significance levels.

    • Main Results:

    • The proposed method allows for a data-driven significance level calculation.
    • This approach aims to enhance the power of tests for batch differences.
    • Illustrative examples demonstrate the comparative performance against the FDA guideline.

    Conclusions:

    • The proposed method offers a more nuanced approach to pooling stability data from multiple batches.
    • By fixing statistical power, this method optimizes the significance level for batch homogeneity testing.
    • This can lead to more reliable shelf-life estimations in pharmaceutical development.